New obesity drugs enter human trials in china

NCT ID NCT07017179

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests two experimental drugs, AZD6234 and AZD9550, given as weekly injections to Chinese adults with obesity or overweight. About 871 participants will receive the drugs alone, together, or a placebo. The main goal is to check safety and how well the drugs work for weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6234 and AZD9550 (injectable drugs for weight loss)
What this could lead to: If successful, these drugs could offer a new option for weight management in people with obesity or overweight.
What could go wrong: This is an early phase 2 trial, so the drugs may not prove effective or safe enough. Side effects are possible, and results may not apply to non-Chinese populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Research Site

Jinan, 250001, China
Research Site

Nanjing, 210011, China
Research Site

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.